These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 22200720)
1. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer]. Li Y; Wang JJ Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720 [TBL] [Abstract][Full Text] [Related]
2. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Hardt PD; Ewald N Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806 [TBL] [Abstract][Full Text] [Related]
3. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312 [TBL] [Abstract][Full Text] [Related]
4. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802 [TBL] [Abstract][Full Text] [Related]
5. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313 [TBL] [Abstract][Full Text] [Related]
6. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127 [TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. Caviglia GP; Cabianca L; Fagoonee S; Gili FM Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025 [TBL] [Abstract][Full Text] [Related]
8. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test. Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070 [TBL] [Abstract][Full Text] [Related]
9. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916 [TBL] [Abstract][Full Text] [Related]
10. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517 [TBL] [Abstract][Full Text] [Related]
11. Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: A meta-analysis. Huang JX; Zhou Y; Wang CH; Yuan WW; Zhang ZD; Zhang XF J Cancer Res Ther; 2014 Nov; 10 Suppl():C225-8. PubMed ID: 25450288 [TBL] [Abstract][Full Text] [Related]
13. [Comparison of different stool tests for the detection of cancer of the colon]. Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820 [TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Schneider J; Schulze G Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971 [TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. Tonus C; Neupert G; Sellinger M World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. Kaura B; Bagga R; Patel FD J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054 [TBL] [Abstract][Full Text] [Related]
18. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469 [TBL] [Abstract][Full Text] [Related]
19. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. Tonus C; Sellinger M; Koss K; Neupert G World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551 [TBL] [Abstract][Full Text] [Related]
20. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma]. Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]